Severe irreversible bilateral hearing loss after bortezomib (VELCADE®) therapy in a multiple myeloma (MM) patient

被引：14
|
作者：
Engelhardt, M
Müller, AMS
Maier, W
Wäsch, R
机构：
[1] Univ Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany
[2] Univ Freiburg, Dept Otolaryngol, D-7800 Freiburg, Germany
来源：
LEUKEMIA | 2005年 / 19卷 / 05期
关键词：
D O I：
10.1038/sj.leu.2403723
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：869 / 870
页数：2
相关论文
共 50 条
  • [1] Severe irreversible bilateral hearing loss after bortezomib (VELCADE®) therapy in a multiple myeloma (MM) patient
    M Engelhardt
    A M S Müller
    W Maier
    R Wäsch
    Leukemia, 2005, 19 : 869 - 870
  • [2] Multiple myeloma:: Increase of the effectiveness of Velcade® (Bortezomib) through combination therapy
    Aschoff, K
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2005, 32 (05) : 284 - 284
  • [3] Multiple myeloma:: Increase of the effectiveness of Velcade® (Bortezomib) through combination therapy
    不详
    ONKOLOGIE, 2005, 28 (11): : 608 - 608
  • [4] Bortezomib (VELCADE™, formerly PS-341) as first-line therapy in patients with multiple myeloma (MM).
    Jagannath, S
    Durie, BGM
    Wolf, J
    Berliner, A
    Camacho, E
    Gabayan, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Potts, P
    Noble-Kempin, S
    Davis, B
    Mazumder, A
    Crowley, J
    Jacobson, J
    Schenkein, D
    BLOOD, 2003, 102 (11) : 452A - 452A
  • [5] Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
    Evangelos Terpos
    Marianna Politou
    Amin Rahemtulla
    Journal of Cancer Research and Clinical Oncology, 2004, 130 : 623 - 625
  • [6] Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
    Terpos, E
    Politou, M
    Rahemtulla, A
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (10) : 623 - 625
  • [7] Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma
    Joh, Tatsuro
    Sigematu, Kazuto
    Yasui, Jun-Ichi
    Takasaki, Yumi
    Tawara, Masayuki
    Takahara, Osamu
    Tomonaga, Masao
    CASE REPORTS IN ONCOLOGY, 2009, 2 (03): : 184 - 188
  • [8] CLINICAL EFFICACY OF VELCADE (BORTEZOMIB) AND DEXAMETHASONE THERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA
    Ionita, I.
    Cheveresan, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 627 - 628
  • [9] Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM)
    Richardson, PG
    Chanan-Khan, A
    Schlossman, RL
    Munshi, NC
    Wen, P
    Briemberg, H
    Kuter, D
    Oaklander, AL
    Lonial, S
    Hassoun, H
    Doss, D
    Colson, K
    McKenney, M
    Hande, K
    Koryzna, A
    Stoklas, B
    Lunde, L
    Gorelik, S
    McAlister, C
    Freeman, A
    Warren, D
    Collins, D
    Esseltine, D
    Amato, A
    Anderson, KC
    BLOOD, 2004, 104 (11) : 100A - 100A
  • [10] Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM)
    Mateos, Maria-Victoria
    Oriol, Albert
    Rosinol, Laura
    de Arriba, Felipe
    Martin, Jesus
    Martinez-Lopez, Joaquin
    Asuncion Echeveste, Maria
    Sarra, Josep
    Ramirez, Gemma
    Ocio, Enrique M.
    Martinez, Rafael
    Palomera, Luis
    Payer, Angel
    Iglesias, Rebeca
    De La Rubia, Javier
    Alegre, Adrian
    Chinea, Anabelle
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
12345